Maj Invest Holding A S Sells 78,471 Shares of Zoetis Inc. $ZTS

Maj Invest Holding A S reduced its position in Zoetis Inc. (NYSE:ZTS) by 11.6% during the second quarter, Holdings Channel reports. The institutional investor owned 596,697 shares of the company’s stock after selling 78,471 shares during the quarter. Zoetis comprises 1.9% of Maj Invest Holding A S’s investment portfolio, making the stock its 18th largest holding. Maj Invest Holding A S’s holdings in Zoetis were worth $42,877,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. RFG Advisory LLC boosted its stake in Zoetis by 4.9% in the fourth quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock valued at $215,000 after acquiring an additional 80 shares in the last quarter. Quest 10 Wealth Builders Inc. increased its position in shares of Zoetis by 4.7% during the fourth quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock worth $240,000 after purchasing an additional 86 shares in the last quarter. Financial Engines Advisors L.L.C. increased its position in shares of Zoetis by 4.4% during the third quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock worth $299,000 after purchasing an additional 87 shares in the last quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych lifted its holdings in shares of Zoetis by 20.9% during the 4th quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 520 shares of the company’s stock valued at $65,000 after purchasing an additional 90 shares during the last quarter. Finally, Physician Wealth Advisors Inc. lifted its holdings in shares of Zoetis by 17.4% during the 1st quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock valued at $73,000 after purchasing an additional 91 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Insiders Place Their Bets

In related news, Director Frank A. Damelio bought 6,650 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The shares were purchased at an average cost of $75.39 per share, with a total value of $501,343.50. Following the completion of the acquisition, the director directly owned 21,458 shares in the company, valued at approximately $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael B. Mccallister purchased 3,000 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was bought at an average cost of $77.76 per share, with a total value of $233,280.00. Following the completion of the acquisition, the director directly owned 24,524 shares of the company’s stock, valued at $1,906,986.24. This trade represents a 13.94% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have purchased 11,650 shares of company stock valued at $886,384. Company insiders own 0.22% of the company’s stock.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $72.53 on Friday. Zoetis Inc. has a twelve month low of $71.47 and a twelve month high of $160.48. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The company has a market cap of $30.41 billion, a PE ratio of 11.95, a price-to-earnings-growth ratio of 1.26 and a beta of 0.74. The company’s 50 day moving average is $76.66 and its 200 day moving average is $100.75.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 70.95%. The business’s quarterly revenue was down .2% compared to the same quarter last year. During the same period in the previous year, the business posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, sell-side analysts forecast that Zoetis Inc. will post 6.43 EPS for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is presently 34.93%.

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis reported second-quarter adjusted earnings of $1.87 per share, above the $1.84–$1.85 analyst consensus and up from $1.76 a year earlier. The earnings beat provides some support for the stock. Zoetis Surpasses Q2 Earnings Estimates
• Positive Sentiment: JPMorgan lowered its price target from $130 to $115 but maintained an Overweight rating, implying substantial potential upside from recent levels. The target reduction reflects more conservative estimates rather than a bearish long-term view.
• Neutral Sentiment: Zoetis appointed James “Jay” Saccaro as executive vice president and chief financial officer, with the announcement also describing an expanded finance and operating leadership role. The change may improve execution, but its near-term effect on results is unclear. Zoetis Appoints Jay Saccaro
• Negative Sentiment: Second-quarter revenue was $2.47 billion, below the $2.50 billion consensus and essentially flat year over year. Management cited weaker veterinary traffic, customer price sensitivity and competitive pressure in companion-animal products, with promotions being used to defend market share. ZTS Q2 Earnings Call Flags Deeper Companion Animal Pressure
• Negative Sentiment: Zoetis cut fiscal 2026 guidance to adjusted EPS of $6.15–$6.25 from expectations near $6.87, and revenue guidance to $9.1–$9.3 billion versus consensus of roughly $9.8 billion. The outlook reduction is the primary reason the stock has declined despite the quarterly earnings beat. Zoetis Q2 Earnings Beat Estimates, Revenues Miss, 2026 View Cut

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on ZTS shares. Morgan Stanley set a $85.00 price objective on Zoetis in a research report on Friday. William Blair restated a “market perform” rating on shares of Zoetis in a research note on Thursday. Wall Street Zen cut shares of Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Argus reissued a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Finally, UBS Group cut their target price on Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a research report on Friday. Seven analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Zoetis has a consensus rating of “Hold” and an average target price of $115.50.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.